Transformative Antisense Therapy
Targeting the Root Cause of CF
Our innovative mRNA-based therapies, based on Antisense Oligonucleotides (ASOs) fully restore protein functionality, addressing currently untreatable genetic pulmonary illnesses.
Clinically Validated Technology
SpliSense is an Israel-based company developing transformative mRNA-based treatments for unmet needs relating to CF and other genetic pulmonary illnesses. Our treatment is based on clinically-validated Antisense Oligonucleotide (ASO) technology, delivered non-invasively by inhalation. We are focused on a variety of innovative therapies, in clinical stages from discovery to IND enabling studies.
News and Video
SpliSense is excited to share its most recent press release, announcing the successful completion a first-in-human, Phase 1 clinical trial of SPL84, the company’s lead anti sense oligonucleotide (ASO) product for the treatment of patients with CF, carrying the unmet 3849-splicing mutation.
